Multiple myeloma

Multiple myeloma — formally, plasma cell myeloma — begins in plasma cells, the immune system’s final-stage B-lymphocytes: each one, normally, secretes a specific antibody against a specific threat. Myeloma begins when one plasma cell acquires the mutations to clone itself indefinitely. The clone fills marrow space, and everything characteristic about the disease follows from what a plasma cell clone does. It secretes: a single monoclonal antibody — the M-protein detectable in blood, and often free light chains, fragments small enough to pass into and clog the kidneys. It signals: the clone activates bone-dissolving osteoclasts while suppressing bone-building osteoblasts, punching the lytic lesions that give myeloma its X-ray signature and releasing calcium into the blood. And it crowds: normal blood production and normal antibody output both fall, producing anaemia and an immune paradox — a marrow full of antibody factories in a patient prone to infection, because the factories all make the same useless product.

Myeloma is a disease of later life — the typical patient is in their late sixties — modestly commoner in men, and roughly twice as common in people of African descent, for reasons partly genetic. It almost never appears from nowhere: essentially every case evolves from a silent precursor, MGUS (monoclonal gammopathy of undetermined significance), through an intermediate called smouldering myeloma. MGUS is common in older populations and overwhelmingly harmless — it progresses to myeloma at only about one percent per year — but the sequence matters clinically: it explains the surveillance rather than treatment offered to precursor states, and it reframes diagnosis not as “has the clone appeared?” but “has the clone begun to do damage?”. That question — damage — is written directly into the diagnostic criteria this page describes next.

One more orientation point: myeloma is genuinely heterogeneous, with chromosomal events (translocations, deletions — del(17p) the most notorious) sorting patients into standard- and high-risk biology that modern staging incorporates. Two patients with identical symptoms can carry very different diseases, and increasingly, receive different plans.

Myeloma care is organised as a long-term outpatient relationship punctuated by defined episodes: the diagnostic fortnight, induction’s weekly visits, the transplant admission where taken, then maintenance’s monthly rhythm stretching into years. Continuity is the system’s quiet asset — the same team reading the same M-protein graph across a decade — and it is worth protecting deliberately when circumstances (or treatment abroad for the transplant episode) split care across institutions: one shared, updated response graph travels with the patient, or the story fragments exactly where it matters most.

Myeloma’s trouble is that its symptoms impersonate ordinary ageing. The commonest presenting complaint is bone pain — most often persistent back or rib pain, worse with movement, occasionally announced brutally by a fracture from minimal strain or a collapsing vertebra. Any older adult whose “mechanical” back pain persists, wakes them at night, or comes with the other features here deserves the simple blood tests that catch this disease.

The rest of the CRAB quartet each has a voice. High calcium speaks as thirst, frequent urination, constipation, nausea, confusion and drowsiness — an insidious cluster easily blamed on age or medication. Renal injury is usually silent until advanced, occasionally abrupt: myeloma is one of medicine’s classic causes of unexplained kidney failure in an older adult, and every nephrology unit screens for it. Anaemia produces the fatigue and breathlessness that patients most often actually feel — tiredness out of proportion, present for months. Beyond CRAB: recurrent infections (particularly chest and urinary) from the antibody paradox; weight loss; and in a minority, symptoms from the M-protein itself — hyperviscosity (blurred vision, headaches, oozing bleeding) when levels are very high, or neuropathy.

Two emergencies hide in this symptom landscape and justify their own flags below: spinal cord compression, from a vertebral fracture or a plasma cell tumour pressing on the cord — back pain with leg weakness, numbness, or bladder/bowel change — where hours matter for walking; and severe hypercalcaemia, where confusion and dehydration spiral. Both are treatable, and both punish delay.

Height loss is the sign nobody reports: vertebral compression happens vertebra by vertebra, painful sometimes, silent often, and a person who has “shrunk” several centimetres across a few years — trousers longer, cupboards higher — has a skeleton that deserves imaging. Clinics measure height for exactly this reason; families who notice the stoop before the clinic does should say so.

Myeloma’s cause story is mostly a biology story rather than an exposure story. The malignant transformation happens in a plasma cell whose antibody-gene machinery — built to cut and rejoin DNA — misfires, creating the founding translocations that sit in roughly half of all cases (the rest begin with extra chromosome copies, the hyperdiploid route). Additional hits accumulate over years inside the MGUS-to-myeloma sequence; which precursor clones progress, and why, is an active research frontier — no test yet separates the MGUS that will smoulder harmlessly for decades from the one that will not, which is why precursor states are monitored, not treated, outside trials.

The established external associations are few and modest. Age is the dominant factor — risk climbs steeply after sixty. African ancestry roughly doubles incidence, with corresponding differences in MGUS prevalence suggesting the difference operates at the precursor step. First-degree relatives of myeloma or MGUS patients carry a modestly increased risk — familial clustering is real but small, and no screening of relatives is recommended. Obesity is the clearest modifiable association. High-dose radiation exposure and certain occupational exposures (pesticides — including findings in agricultural cohorts — benzene, firefighting) appear repeatedly in epidemiology at modest strength; the herbicide component of some of these literatures remains debated. Notably absent: infection is a consequence rather than a cause; no diet causes myeloma; and nothing in the list above explains any individual case — the honest counsel for almost every patient is that this arose from decades of invisible cellular chance, not from anything done or left undone.

The ancestry pattern carries one practical corollary worth stating: because myeloma is roughly twice as common in people of African descent and presents younger on average, symptom thresholds — the persistent back pain, the unexplained anaemia — deserve slightly quicker laboratory attention in that population, and research programmes have begun correcting a historic under-representation. Risk difference is not destiny; it is a reason for earlier blood tests, nothing more.

The profile in brief: age over sixty (the median diagnosis sits in the late sixties); male sex, modestly; African descent, roughly twofold; an existing MGUS — the universal precursor, with its ~1% annual progression rate — or smouldering myeloma, whose progression risk is front-loaded in its first years and graded by marker levels; family history of myeloma or MGUS, modestly; obesity; and the occupational and radiation exposures noted above. MGUS deserves the practical emphasis: it is found incidentally in a few percent of older adults, it does NOT need treatment, and it DOES need periodic blood monitoring — an arrangement whose entire purpose is to catch the minority conversion at the paper stage rather than the fracture stage. Anyone told they have MGUS should know the follow-up plan and keep it.

Two ladders coexist. The first is the disease-definition ladder — MGUS, smouldering, active myeloma — which decides WHETHER to treat. The second is the staging ladder for active disease — the Revised International Staging System (R-ISS) — which combines blood markers with high-risk genetics to forecast pace. Unlike solid-tumour staging, none of it maps where disease sits — imaging does that separately — and none of it expires: restaging language at relapse reuses the same vocabulary with updated numbers, which is why keeping personal copies of the original reports pays off for years.

Myeloma diagnostics answer three questions in sequence. Is there a clone? Blood and urine electrophoresis with immunofixation find and type the monoclonal protein (M-protein); the serum free light chain assay catches the cases — including the light-chain-only and rare non-secretory variants — that electrophoresis alone can miss. A bone marrow aspirate and biopsy then quantify clonal plasma cells and feed the critical genetics: FISH testing for the high-risk lesions (del(17p), t(4;14), t(14;16) and others) that staging and drug choice now lean on.

What has it broken? The CRAB survey: calcium, creatinine and eGFR, full blood count — and modern whole-body imaging. Here practice has moved decisively: low-dose whole-body CT, PET-CT or whole-body MRI have replaced the old skeletal X-ray survey, which missed early lesions; MRI is the arbiter for suspected cord compression and for the focal lesions that count among the SLiM criteria. Urine assessment quantifies light-chain load where kidneys are threatened.

And how will it be tracked? The same M-protein and light-chain numbers become the response gauges of treatment, marrow reassessment marks the deep milestones, and minimal residual disease (MRD) testing — flow cytometry or sequencing finding one cell in a hundred thousand or better — has entered guidelines as the deepest response measure, increasingly steering trial design and, at advanced centres, maintenance decisions. Baseline organ work rounds out the file for treatment planning: heart assessment (relevant to some regimens and to transplant), virology screening, and — for anyone conceivably transplant-eligible — early discussion of stem cell collection timing, since some drugs given long can hamper later harvests.

Interpreting the first reports, two translations help families most. “Smouldering” is not a softer cancer but a WAITING one — the distinction is damage, not biology, and the surveillance it earns is protective, not dismissive. And the free light chain numbers, which look alarming in isolation (hundreds or thousands of mg/L), only carry meaning through their RATIO and their TREND: a falling involved-chain under treatment is the sentence being written, whatever any single value reads. Clinics that graph these numbers for patients — most now do — turn a frightening lab sheet into a legible story.

The recurring numbers of a myeloma file, and what each one is doing.

Myeloma’s complications are concentrated where its biology points. Bone disease leads: lytic lesions weaken the skeleton’s weight-bearing architecture, producing pathological fractures and vertebral collapses that can cascade into height loss, chronic pain and — the emergency above — cord compression. Bone-protecting drugs (zoledronic acid, denosumab) are therefore part of standard therapy, with dental review beforehand because jaw osteonecrosis is their rare signature risk; radiotherapy palliates focal lesions; vertebroplasty and surgical stabilisation have their places. Kidney injury is the second front: light chains clog and inflame the tubules (“myeloma kidney”), abetted by calcium, dehydration and NSAIDs — a fraction of patients present in kidney failure, and rapid diagnosis-plus-treatment can rescue substantial function, which is why myeloma is on every unexplained-renal-failure checklist. A related deposition disease, AL amyloidosis, travels with a minority of clones and gets its own testing when hearts, kidneys or nerves misbehave beyond myeloma’s usual script.

Infection is the quiet killer across the course: the antibody paradox, treatment immunosuppression and age combine, making vaccination (influenza, pneumococcus, COVID-19; non-live vaccines on schedule), prompt antibiotics and — in defined settings — prophylaxis into survival tools rather than footnotes. Hypercalcaemia and hyperviscosity are the metabolic emergencies. And treatment contributes complications of its own worth naming because they are managed, not merely endured: peripheral neuropathy (bortezomib’s signature, mitigated by weekly subcutaneous dosing and dose care), blood clots on immunomodulatory drugs (aspirin or anticoagulant prophylaxis is standard), steroid effects — mood, glucose, sleep — that patients should report rather than suffer, cytopenias, and with the newest immunotherapies, infection risks profound enough to carry their own monitoring protocols.

Peripheral neuropathy earns its own management paragraph because it is the toxicity patients most often under-report until it is entrenched: tingling, numbness or burning in feet and fingertips on bortezomib or thalidomide-class drugs is a REPORT-NOW symptom — dose adjustment or switching at the first signs usually prevents progression, while stoic silence can leave permanent damage. The same rule covers sudden calf swelling or breathlessness on immunomodulators: clot symptoms outrank clinic schedules.

Primary prevention of myeloma is not currently possible in any meaningful sense: its strongest risk factors — age, ancestry, the precursor clone itself — are not modifiable, and no diet, supplement or screening programme for the general population has evidence. Weight management earns its mention as the one modifiable association, valuable for many reasons beyond this one.

What CAN be prevented, with high yield, sits in three places. First, progression caught early: people with known MGUS or smouldering myeloma who keep their monitoring schedule convert the disease’s first act from a fracture or kidney crisis into a blood-test trend — the SLiM criteria exist precisely to authorise treatment at that paper stage, and high-risk smouldering patients should hear about trials. Second, complications pre-empted: bone agents started with treatment, dental review before them; hydration and NSAID-avoidance as standing kidney rules; vaccination kept current; clot prophylaxis alongside the drugs that need it; and the emergency symptoms — new leg weakness, confusion, fever on therapy — rehearsed with family the way this page’s red-flag box frames them. Third, treatability preserved: for potentially transplant-eligible patients, planning stem cell collection at the right moment protects an option that prolonged exposure to some drugs can erode. None of this is dramatic; jointly, in registry after registry, this unglamorous maintenance work separates the smoother courses from the harder ones.

Driving, lifting and activity rules come up at every first consultation and have real answers: with significant spinal lesions, heavy lifting and high-impact activity wait for treatment response and bone-agent cover, while walking and supervised physiotherapy start immediately — immobility thins bone faster than myeloma does. Most patients drive, work part-time through induction where fatigue allows, and return to fuller activity in maintenance; the skeleton’s repair under effective treatment is real, measurable on scans, and one of this disease’s quiet encouragements.

Modern myeloma treatment is built from drug classes layered into combinations: proteasome inhibitors (bortezomib, carfilzomib, ixazomib), immunomodulatory drugs (lenalidomide, pomalidomide), anti-CD38 monoclonal antibodies (daratumumab, isatuximab), and corticosteroids — with newer immunotherapies (the anti-BCMA CAR-T products and bispecific antibodies such as teclistamab, plus belantamab’s antibody-drug conjugate class) transforming the relapsed setting and moving earlier in trials. First-line therapy for a fit, transplant-eligible patient now typically means a three- or four-drug induction — daratumumab-VRd-type quadruplets having shown deeper responses in recent trials — followed by stem cell collection, high-dose melphalan with autologous transplant, and lenalidomide-based maintenance until progression: a sequence, not a single treatment, whose milestones (response depth, MRD status) are tracked at every junction. Transplant-ineligible patients receive continuous combination therapy — daratumumab-lenalidomide-dexamethasone the prominent standard — dosed to age and frailty with outcomes that have risen steadily.

Relapse, in myeloma, is expected rather than exceptional, and the field’s depth shows there: each return is met by switching classes, guided by what was used, what lasted, refractoriness patterns and genetics; second transplants serve selected long first remissions; and the BCMA-directed immunotherapies — CAR-T (ide-cel, cilta-cel) and bispecifics — have produced deep responses in heavily pretreated disease, with access, logistics and their distinctive toxicities (cytokine release, infections) shaping who gets them where. Trial participation deserves its standing sentence in myeloma above almost any cancer: the treatment landscape turns over so quickly that today’s trial arm is routinely tomorrow’s standard, most academic centres run open studies at every disease stage, and asking “is there a trial that fits me?” at each decision point is simply how well-informed myeloma care is practised. Supportive care runs throughout as co-equal treatment: bone agents, kidney protection, infection defence, thrombosis prophylaxis, pain control, fitness maintenance.

Two framing truths belong in every treatment conversation. Myeloma today is a marathon of sequenced therapies in which many patients live a decade and more, with the plan revised at each stage — so second opinions and trial questions are normal parts of care, not disloyalty. And the pace of change is real: several standards named in this paragraph were experimental five years ago, which is why the sources below, not any static page, are the durable reference.

Supportive care earns co-billing with the anti-myeloma drugs because it is where daily quality of life is decided: bone agents with dental review; thrombosis prophylaxis with the immunomodulators; infection defence — vaccines, prompt antibiotics, immunoglobulin replacement in selected recurrent cases; kidney protection’s standing rules (hydration, no NSAIDs); pain managed properly, including radiotherapy for focal bone pain, which works quickly and is underused; and physiotherapy-led activity, which protects the skeleton better than the instinctive rest does. Patients report steroids as the hardest-lived part of many regimens — the sleepless, wired dexamethasone days — and dose-softening for exactly that complaint is routine, asked for.

The transplant in myeloma is AUTOLOGOUS — the patient’s own stem cells — and its logic differs from every donor transplant on this platform: it is not a rescue from marrow failure or a new immune system, but a delivery mechanism. High-dose melphalan is among the most effective single anti-myeloma treatments known, at a dose that destroys marrow; harvesting the patient’s stem cells first and returning them after allows that dose to be given safely, with blood production restored within about two weeks. Decades of trials — sustained into the era of modern induction — keep showing the same result: adding this consolidation deepens response and lengthens remission, which is why every guideline still routes fit patients through it, even as debates continue about timing (upfront versus at first relapse, with cells banked) and about whether MRD-negative patients on quadruplets might someday skip it. Those debates are for the clinic; the current standard remains as stated.

Eligibility is a fitness judgement, not an age cut-off: biological age, heart, lungs, kidneys (myeloma’s renal damage complicates but rarely excludes — transplants proceed on dialysis in experienced hands) and disease control after induction. The practical sequence a patient experiences: induction cycles; mobilisation and apheresis (a day-case-like collection of stem cells from the bloodstream, occasionally needing the mobilising agent plerixafor); cryostorage; admission for melphalan and cell return; the two-to-three-week engraftment window with its mucositis and infection precautions; then recovery and maintenance. Tandem (double) transplants retain a role in some high-risk protocols; allogeneic (donor) transplant in myeloma is uncommon — reserved for selected young, high-risk patients, essentially always within trials or specialist programmes, its graft-versus-myeloma promise historically offset by toxicity.

For international patients this is one of the most portable major treatments in haematology: a planned, self-contained episode of roughly six to eight weeks including work-up and early recovery, ideally with collection, storage and transplant under one roof, sequenced after induction at home where that is the family’s architecture. The file a centre needs: diagnostic marrow and FISH reports, the M-protein and light-chain graph from diagnosis onward, induction details and response, imaging, kidney trajectory, and cardiac assessment. What no centre — and no platform — can honestly promise is cure: the transplant buys depth and time, which in this disease are the currency that matters. The stem cell transplant guide describes the procedure itself.

Myeloma’s outlook has improved as steadily as any cancer’s over the past twenty-five years — each drug class shifting the survival curves, so that published medians describe cohorts treated with yesterday’s standards. The honest modern framing: most patients respond deeply to first-line therapy; remissions are measured in years and are longest in standard-risk, transplant-consolidated, maintenance-treated disease; relapses are expected and repeatedly treatable through sequenced classes; and a substantial fraction of today’s patients — particularly those achieving sustained MRD negativity — are living beyond a decade, with the word “functional cure” beginning to appear, cautiously, in the literature for the best-responding subset. High-risk genetics (del(17p) prominently), advanced age with frailty, and presentation through kidney failure still mark the harder courses, and the field’s energy — quadruplets, CAR-T moving earlier, bispecific combinations — is aimed exactly there.

What this means for a reader with a new diagnosis: the statistics most worth having are personal ones — R-ISS stage, FISH results, response depth after induction, MRD status — assembled within the first months and updated at each milestone; the questions most worth asking are about sequence — what is the plan for THIS remission, and what is held in reserve; and the disease, while rarely curable, has become one where planning years ahead — work, travel, family decisions, and yes, treatment abroad for a defined episode like the transplant — is not optimism but ordinary prudence. The sources below are chosen because they update as the field moves; in myeloma, that is a feature a static page cannot honestly replicate.

The lived pattern of long-term myeloma, as survivor cohorts describe it: stretches of maintenance-normal life measured in years, punctuated by relapse workups and regimen changes that feel like re-diagnosis and settle into the next stretch; a gradually accumulating expertise in one’s own disease (most long-term patients can read their own light-chain graph); and an unusual dependence, among cancers, on the relationship with one team over time. Patient organisations in this disease are correspondingly strong and evidence-literate — the ones cited below run helplines, trial matchers and treatment guides that clinicians themselves recommend.